Uterine Fibroid Embolization Study

Biodegradable Agent for Treating Uterine Fibroids

 

Occlusin® 500 Embolization Microspheres

 

A research study at the University of Alberta Hospital is seeking participants to determine the safety and effectiveness of a fully biodegradable embolic agent for treating uterine fibroids. This agent breaks down into carbon dioxide and water. The embolic agent blocks the blood supply to the fibroids with the intent of causing the fibroids to shrink and decrease patient symptoms.

 

Premenopausal women that have symptomatic uterine fibroids are eligible for the study.

 

If you are interested in receiving more information please mention this at your clinic appointment or contact:

 

Phone: 780-407-8365  Interested participants MUST contact the clinical site directly.

 

Dr. Richard Owen (rowen@ualberta.ca) or

Joanne McGoey (joanne.mcgoey@albertahealthservices.ca)

Marny Hals (marny.hals@albertahealthservices.ca)

 

Study Details can be viewed on ClinicalTrials.gov website: 

ClinicalTrials.gov - Occlusin Fibroid Study